🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Xiamen Amoytop Biotech clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Xiamen Amoytop Biotech as lead sponsor. Synced 26 Sep 2026
9Current trials
6Recruiting now
5Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Xiamen Amoytop Biotech is the lead sponsor of 9 current clinical trials in our China register. 6 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are Inpegsomatropin, ACT500 and Peginterferon α-2b. The most-studied condition is Chronic Hepatitis B.

ClinicalTrials.gov trials by status

  • Recruiting667%
  • Not yet open222%
  • By invitation111%

Trials by phase

  • Phase 1333%
  • Phase 3333%
  • Phase 2222%
  • Not applicable111%
01

Clinical trials sponsored by Xiamen Amoytop Biotech

9 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Safety, Pharmacokinetic (PK) Profile and Efficacy of Inpegsomatropin Injection in Adults With Growth Hormone Deficiency
NCT07551804 · ClinicalTrials.gov ↗ · Adult Growth Hormone Deficiency
Phase 2 Recruiting 2026-06 China
The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational Age
NCT07309562 · ClinicalTrials.gov ↗ · Small for Gestational Age
Phase 3 Recruiting 2026-01 China
The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature
NCT06927310 · ClinicalTrials.gov ↗ · Idiopathic Short Stature
Phase 3 Recruiting 2025-04 China
ACT201 Injection in Healthy Participants and Participants With Chronic Hepatitis B (CHB)
NCT07741461 · ClinicalTrials.gov ↗ · Chronic Hepaititis B
Phase 1 Recruiting 2026-08 China
Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET
NCT06552429 · ClinicalTrials.gov ↗ · Essential Thrombocythemia
Phase 2 Recruiting 2024-08 China
The Efficacy and Safety of Inpegsomatropin Injection in Children With Turner Syndrome (TS) and Short Stature
NCT07614152 · ClinicalTrials.gov ↗ · Turner Syndrome
Phase 3 Recruiting 2026-07 China
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of ACT500 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Complicated With Chronic Hepatitis B
NCT07589400 · ClinicalTrials.gov ↗ · Metabolic Dysfunction-associated Steatotic Liver Disease, Chronic Hepatitis b
Drug: ACT500
Phase 1 Not yet open 2026-10 China
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic(PK/PD) Profile of ACT500 in Metabolic Dysfunction-Associated Steatotic Liver Disease(MASLD)
NCT07462455 · ClinicalTrials.gov ↗ · Metabolic Dysfunction-associated Steatohepatitis
Drug: ACT500
Phase 1 Not yet open 2026-10 China
A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B
NCT06707922 · ClinicalTrials.gov ↗ · Chronic Hepatitis B
Not applicable By invitation 2022-03 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Xiamen Amoytop Biotech trials

5 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Xiamen Amoytop Biotech trials

10 conditions
Chronic Hepatitis B1Metabolic Dysfunction-associated Steatotic Liver Disease1Chronic Hepatitis b1Adult Growth Hormone Deficiency1Small for Gestational Age1Idiopathic Short Stature1Chronic Hepaititis B1Essential Thrombocythemia1Metabolic Dysfunction-associated Steatohepatitis1Turner Syndrome1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China96

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Chronic Hepatitis B

SponsorTrials
Ausper Biopharma8
The Second Affiliated Hospital of Chongqing Medical University3
Beijing 302 Hospital2
Beijing Municipal Administration of Hospitals2
Xi'an Xintong Pharmaceutical Research1
Fujian Akeylink Biotechnology1
Grand Theravac Life Sciences (Nanjing)1

Sponsors with the most current trials registered for this condition.

06

Questions about Xiamen Amoytop Biotech trials

How many clinical trials does Xiamen Amoytop Biotech sponsor?

Xiamen Amoytop Biotech is the lead sponsor of 9 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Xiamen Amoytop Biotech trials recruiting?

Yes. 6 of its 9 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Xiamen Amoytop Biotech testing?

Its current trials name 5 drugs and biologicals as interventions. The most frequent are Inpegsomatropin (4), ACT500 (2), Peginterferon α-2b (2), Recombinant Human Growth Hormone (2) and Tenofovir Alafenamide Fumarate (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.